



Immunoglobulin Database

Annual Report 2022/23

February 2024



Compiled by
Mark Foster MDSAS

1

Database Overview

Mark Foster

National Immunoglobulin Database Annual Report

This report provides an analysis of immunoglobulin usage across England & Northern Ireland for the 2022/23 financial year. All datasets used are consistent with previous Annual Reports.

Updates from the Commercial Medicines Unit and the Blood Transfusion Service are included in this report.

We plan for the 2023/24 Annual Report to include updates on the following items:

1. NHSE commissioning update
2. Immunoglobulin Management Plan implementation (IMP)
3. Clinical Commissioning Policy (CCP) updates

All immunoglobulin therapies should adhere to NHS England commissioning policy. View the Clinical Commissioning Policy with this link [cpag-policy-for-therapeutic-immunoglobulin-2021-update.pdf \(england.nhs.uk\)](https://www.nhs.uk/clinical-commissioning/pag-policy-for-therapeutic-immunoglobulin-2021-update.pdf)

Information Service

The Immunoglobulin Information service is now redundant. A reporting portal built in Power BI is replacing the Information Service. The Immunoglobulin Power BI Platform has been demonstrated to multiple stakeholders receiving incredibly positive feedback. We'll send out an official communication confirming when the Immunoglobulin Power BI Platform is officially released.

Suggestions or comments are always welcome, please contact support@mdsas.com

2

Commercial Medicines Unit

Darryn Boardman

Framework

NHS England's Medicines Procurement and Supply Chain (MPSC) team, formerly named the Commercial Medicines Unit (CMU), is responsible for the tendering, contract and supply management of the framework for Human Normal Immunoglobulin (Ig) in England, Northern Ireland and Scotland.

The framework provides a compliant route for hospitals to buy high cost medicines without running local tenders, supporting clinical flexibility, best patient care and value for money for the NHS.

The current framework commenced on 1 July 2021 and ran for initial 18 month term. The framework has been extended since the initial term ended and is due to expire on 30 June 2024. There are options to extend the framework until a latest date of 30 June 2025.

The framework provides access to 17 Intravenous, Subcutaneous and Facilitated Subcutaneous Immunoglobulin products from six contracted suppliers. A new tender for the supply of Human Normal Immunoglobulin will be completed in 2024, with the new framework going live in 2025.

Usage

Purchase volumes for the period 1 January 2023 – 31 December 2023 were 6,563,019g.

Volume of 5% Intravenous Immunoglobulin was 270,205g.

Volume of 10% Intravenous Immunoglobulin was 4,494,149g.

Volume of Subcutaneous Immunoglobulin was 1,654,987g.

Volume of Facilitated Subcutaneous Immunoglobulin was 143,678g.

Supply

Availability of Immunoglobulin to England, Northern Ireland and Scotland remained stable throughout 2023.

Despite demand for Immunoglobulins remaining high on a global level, the improved availability of Immunoglobulins has led to the strict Trust allocations being relaxed, resulting in the flexibility for Trusts and regions to adjust their requirements with suppliers in line with their demand.

Supply disruptions on Immunoglobulins have been kept to a minimum during 2023. MPSC have worked closely with suppliers on any minor interruptions to supply, and ensured access to alternative products was available to support patient treatments.

MPSC continue to coordinate with suppliers regarding new and innovative product launches within the category, adding them to current and future frameworks so they can be accessed by hospitals.

Stakeholder Engagement

MPSC continues to work collaboratively with stakeholder groups, and has expanded its involvement on a UK wide level. Working alongside the immunoglobulin oversight group, the immunology and allergy clinical reference group, the neurology clinical reference group and the BSI clinical immunology network has driven improved engagement in all areas.

Regular communication with clinicians, pharmacists, nursing staff and patient groups sits at the heart of our continued drive for improvement at NHS England. We continue to explore avenues to work strategically on frameworks across all devolved administrations, standardising therapies and standards of care.

If any member of the immunoglobulin community would like to participate in future engagement, please reach out on the contact details below.

Contacting CMU

For further information on the framework please contact MPSC at: jennifer.tierney@nhs.net or 07730 371220

3

Blood Transfusion Service

Gerard Gogarty

Plasma for Medicines in England

Since 2021, plasma can now be collected from UK donors and in England, NHS Blood and Transplant (NHSBT) has been working with partners to deliver a programme to build national self-sufficiency in plasma derived medicines. DHSC has been leading on policy and NHSE on fractionator procurement/distribution of medicines to the NHS. NHSBT's role is to leverage its unique infrastructure and specialist capabilities to collect and supply plasma for fractionation.

This is being achieved through two sources of collection, Recovery of Plasma from whole blood (known as Recovered Plasma) and Source Plasma collection via plasmapheresis (known as Source Plasma). NHSBT is currently progressing towards recovery of the majority of non-clinical plasma for medicines with the aim of achieving a minimum of 20% self-sufficiency. Just under 16,000 litres of plasma are currently being recovered each month which will increase during the first half of 2024.

To grow self-sufficiency further, Source Plasma collection from donors is required and NHSBT currently has 3 collection centres in Birmingham, Reading and Twickenham. During 23/24, all three centres have been made permanent and expanded to increase capacity and collection has doubled to 16,000 litres. NHSBT is planning to further increase volumes in 24/25.

NHSBT aim to supply the first plasma for fractionation in mid-2024 and it is anticipated that the first supply of medicines will begin in 2025 in England.

Report	Page	
Table 1.1	Immunology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23	8
Table 1.2	Haematology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23	8
Table 1.3	Neurology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23	9
Table 1.4	Infectious diseases - volume of recorded immunoglobulin and patients on Ig therapy 2022/23	9
Table 1.5	'Others' - volume of recorded immunoglobulin and patients on Ig therapy 2022/23	10
Table 1.6	Non-commissioned - volume of recorded Ig and patients on Ig therapy 2022/23	10
Figure 1.1	Monthly number of patients treated 2022/23	11
Figure 1.2	Yearly number of patients on immunoglobulin therapy 2017/18 - 2022/23	11
Figure 1.3	Monthly number of patients treated by speciality 2022/23	12
Figure 1	Yearly number of patients treated by speciality 2017/18 - 2022/23	12
Figure 1.5	Number of patients on immunoglobulin therapy by commissioning region 2022/23	13
Figure 1.6	Recorded volumes of immunoglobulin by commissioning region 2022/23	13
Table 2.1	Recorded volumes of immunoglobulin and patients on Ig therapy by SRIAP 2022/23	14
Table 2.2	Recorded volumes of immunoglobulin and patients on Ig therapy - top 50 Trusts 2022/23	15-16
Figure 2.1	Monthly recorded volume of immunoglobulin by regime 2022/23	17
Figure 2.2	Yearly recorded volume of immunoglobulin by regime 2017/18 - 2022/23	17
Figure 2.3	Monthly recorded volume of immunoglobulin by speciality 2022/23	18
Figure 2.4	Yearly recorded volume of immunoglobulin by speciality 2017/18 - 2022/23	18
Table 3.1	Recorded volumes of immunoglobulin by brand 2022/23	19
Figure 3.1.1	Monthly number of patients on IV and SC immunoglobulin therapy 2022/23	20
Figure 3.1.2	Yearly number of patients on IV and SC immunoglobulin therapy 2022/23	20
Figure 3.2.1	Monthly recorded volume of IV and SC immunoglobulin 2022/23	21
Figure 3.2.2	Yearly recorded volume of IV and SC immunoglobulin 2022/23	21
Figure 3.3	34Monthly recorded volume of the top 10 IV immunoglobulin products 2022/23	22
Figure 3.4	Yearly recorded volume of the top 10 IV immunoglobulin products 2017/18 - 2022/23	22
Figure 3.5	Monthly recorded volume of subcutaneous immunoglobulin products 2022/23	23
Figure 3.6	Yearly recorded volume of subcutaneous immunoglobulin products 2017/18 - 2022/23	23
Figure 3.7	Monthly recorded volume of immunoglobulin by supplier 2022/23	24
Figure 3.8	Yearly recorded volume of immunoglobulin by supplier 2017/18 - 2022/23	24
Table 4.1	Number of long-term patients on Ig therapy with Follow-Ups recorded 2017/18 - 2022/23	25
Table 4.2	Number of short-term patients on Ig therapy with outcomes recorded 2017/18 - 2022/23	25
Table 4.3	ITP dosage data 2015 - 2023	25

Table 1.1 Immunology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
Primary immunodeficiencies associated with significant antibody defects	3,405	1,225,795
Secondary antibody deficiencies	2,809	762,718
Specific antibody deficiency	242	86,278
Thymoma with immunodeficiency	49	16,789
HSCT in primary immunodeficiencies	52	7,991
Total	6,557	2,099,571

Table 1.2 Haematology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
Immune thrombocytopenic purpura (ITP)	1,417	174,547
Autoimmune haemolytic anaemia	168	22,179
Alloimmune thrombocytopenia	47	20,742
Coagulation factor inhibitors (alloantibodies and autoantibodies)	41	15,495
Haemophagocytic syndrome / Haemophagocytic lymphohistiocytosis (HLH)	90	11,577
Post-transfusion hyperhaemolysis	78	11,128
Acquired red cell aplasia associated with chronic parvovirus B19 infection	26	2,900
Haemolytic disease of the newborn	102	1,453
Post -transfusion purpura	>5	160
Total	1,970	260,179

Table 1.3 Neurology - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
CIDP (including IgG or IgA associated paraprotein associated demyelinating neuropathy)	1,585	1,298,550
Multifocal motor neuropathy - (MMN)	655	644,856
Inflammatory myopathies	404	179,225
Myasthenia gravis	704	176,852
Guillain–Barré syndrome and variants	906	132,552
Stiff person syndrome - (SPS) or variant	95	52,538
IgM Paraprotein-associated demyelinating neuropathy	24	24,080
Autoimmune encephalitides (AIE)	116	18,248
Non-MS CNS inflammatory disease	56	11,210
Rasmussens Encephalitis	10	5,040
Acute idiopathic / autoimmune dysautonomia /ganglionopathy	9	3,240
Paraneoplastic neurological syndromes (PNS) without evidence of autoantibodies	13	2,205
Opsoclonus-myoclonus syndrome	7	825
Neuromyotonia (Isaacs syndrome)	3	510
Total	4,587	2,549,930

Table 1.4 Infectious diseases - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
Toxic Shock Syndrome (TSS)	495	48,044
Viral pneumonitis post-transplantation	31	3,300
Severe or recurrent Clostridium difficile infection (CDI) colitis	58	1,863
Post-exposure prophylaxis or treatment of viral or pathogenic infection	11	700
Tetanus	8	360
Varicella zoster	3	33
Measles	2	5
Hepatitis A	1	1
Total	609	54,305

Table 1.5 'Others' - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
Immunobullous diseases	46	24,131
Transplantation (Solid Organ)	136	17,487
Kawasaki disease	347	13,154
ANCA-associated systemic vasculitides	32	11,205
Allo-immune neonatal haemochromatosis	10	3,438
Autoimmune uveitis	12	2,800
Paediatric inflammatory multisystem syndrome temporally associated to COVID-19	42	2,659
Gestational allo-immune Liver Disease (GALD)	3	2,225
Catastrophic antiphospholipid syndrome	13	1,350
Total	641	78,448

Table 1.6 Non-commissioned - volume of recorded immunoglobulin and patients on Ig therapy 2022/23

Condition	Patients	Grams
Non-commissioned indications	348	138,859
Total	348	138,859

Figure 1.1 Monthly number of patients on immunoglobulin therapy 2022/23




Figure 1.2 Yearly number of patients on immunoglobulin therapy 2017/18 - 2022/23




Figure 1.3 Monthly number of patients on immunoglobulin therapy by speciality 2022/23




Figure 1.4 Yearly number of patients on immunoglobulin therapy by speciality 2017/18 - 2022/23




Figure 1.5 Number of patients on immunoglobulin therapy by commissioning region 2022/23




Figure 1.6 Recorded volumes of immunoglobulin by commissioning region 2022/23




Table 2.1 Recorded volumes of immunoglobulin and patients on Ig therapy by SRIAP 2022/23

Region	Panel	Volume (g)	Patients
N.Ireland	Belfast	244,872	727
N.Ireland Total		244,872	727
London	North Central London	645,459	1,449
	North East London	162,830	470
	North West London	144,019	629
	South London	273,053	1,000
London Total		1,225,360	3,548
Midlands & East	Central / South West Midlands	224,539	678
	East Midlands	354,921	935
	East of England	553,924	1,451
	North / West Midlands	106,433	426
Midlands & East Total		1,239,816	3,490
North	Cheshire & Mersey	183,584	385
	Greater Manchester - Salford	230,181	461
	Greater Manchester & Lancs	142,038	549
	Humber, Coast & Vale	88,362	274
	North & West Yorkshire	235,457	677
	North East & Cumbria	292,951	789
	South Yorkshire	180,441	534
North Total		1,353,013	3,669
South	Kent & Medway	62,822	219
	Peninsula	191,158	480
	South West	255,533	677
	Southampton/Hampshire	231,529	711
	Sussex & Surrey	252,443	629
	Thames Valley	124,045	460
South Total		1,117,531	3,176
Total		5,181,292	14,610

Table 2.2 Recorded volume of immunoglobulin and patients on Ig therapy in the top 50 Trusts 2022/23

Trust	Volume (g)	Patients
University College London Hospitals NHS Foundation Trust	305,986	421
Royal Free London NHS Foundation Trust	273,563	628
Cambridge University Hospitals NHS Foundation Trust	260,216	558
Belfast Health and Social Care Trust	245,573	727
Salford Royal NHS Foundation Trust	217,424	380
The Newcastle Upon Tyne Hospitals NHS Foundation Trust	180,235	399
University Hospitals Birmingham NHS Foundation Trust	158,181	410
Leeds Teaching Hospitals NHS Trust	157,417	438
Sheffield Teaching Hospitals NHS Foundation Trust	153,732	342
University Hospitals of Leicester NHS Trust	144,990	293
The Walton Centre NHS Foundation Trust	134,851	139
Barts Health NHS Trust	133,464	336
Nottingham University Hospitals NHS Trust	118,581	377
North Bristol NHS Trust	113,455	225
Kings College Hospital NHS Foundation Trust	112,668	355
University Hospital Southampton NHS Foundation Trust	109,468	333
Oxford University Hospitals NHS Foundation Trust	92,137	290
Imperial College Healthcare NHS Trust	90,023	291
Frimley Health NHS Foundation Trust	74,285	204
Lancashire Teaching Hospitals NHS Foundation Trust	69,350	127
University Hospitals Plymouth NHS Trust	65,898	219
Royal Cornwall Hospitals NHS Trust	65,855	83
St Georges University Hospitals NHS Foundation Trust	61,311	151
East Suffolk and North Essex NHS Foundation Trust	57,122	157
Guys and St Thomas NHS Foundation Trust	54,436	225

Table 2.2 Recorded volume of immunoglobulin and patients on Ig therapy in the top 50 Trusts 2022/23

Trust	Volume (g)	Patients
Hull University Teaching Hospitals NHS Trust	51,609	146
Norfolk and Norwich University Hospitals NHS Foundation Trust	50,912	86
South Tees Hospitals NHS Foundation Trust	49,431	111
Brighton and Sussex University Hospitals NHS Trust	48,495	95
University Hospitals of North Midlands NHS Trust	44,599	148
East Sussex Healthcare NHS Trust	43,555	85
University Hospitals of Derby and Burton NHS Foundation Trust	41,052	118
Gloucestershire Hospitals NHS Foundation Trust	38,128	95
Royal Devon and Exeter NHS Foundation Trust	36,855	102
Royal Papworth Hospital NHS Foundation Trust	36,629	97
Western Sussex Hospitals NHS Foundation Trust	35,730	91
Manchester University NHS Foundation Trust	32,214	214
Mid Yorkshire Hospitals NHS Trust	32,205	84
Royal United Hospitals Bath NHS Foundation Trust	30,725	59
Maidstone and Tunbridge Wells NHS Trust	29,272	92
Mid Essex Hospital Services NHS Trust	28,250	86
Hampshire Hospitals NHS Foundation Trust	27,635	95
Epsom and St Helier University Hospitals NHS Trust	26,348	114
Royal Surrey County Hospital NHS Foundation Trust	25,546	68
York Teaching Hospital NHS Foundation Trust	25,505	99
Great Ormond Street Hospital for Children NHS Foundation Trust	24,957	189
Barking, Havering and Redbridge University Hospitals NHS Trust	24,591	103
Southend University Hospital NHS Foundation Trust	24,368	76
Great Western Hospitals NHS Foundation Trust	24,345	52
University Hospitals Bristol NHS Foundation Trust	24,283	172

Figure 2.1 Monthly recorded volume of immunoglobulin by regime 2022/23




Figure 2.2 Yearly recorded volume of immunoglobulin by regime 2017/18 - 2022/23




Figure 2.3 Monthly recorded volume of immunoglobulin by speciality 2022/23




Figure 2.4 Yearly recorded volume of immunoglobulin by speciality 2017/18 - 2022/23




Table 3.1 Recorded volumes of immunoglobulin by brand 2022/23

Supplier	Brand	Long Term	Short Term	Total
Intravenous		3,125,134	769,816	3,894,949
Biotest	Intratect 10%	445,222	165,983	610,055
Biotest	Intratect 5%	58,455	27,250	85,705
BPL	Gammaplex 10%	74,343	20,363	94,706
BPL	Gammaplex 5%	980	165	1,145
CSL	Privigen 10%	1,390,499	208,070	1,598,569
Grifols	Flebogamma DIF 5%	124,661	10,235	134,896
Grifols	Gamunex 10%	145,429	25,145	170,574
LFB	Iqymune 10%	255,250	80,029	335,278
Octapharma	Octagam 10%	434,179	61,174	495,353
Octapharma	Octagam 5%	13,465	615	14,080
Octapharma	Panzyga	38,724	97,867	136,591
Takeda	Kiovig 10%	143,043	72,862	215,904
Sub-cutaneous		1,280,756	5,587	1,286,343
BPL	Subgam	100,559	721	101,280
CSL	Hizentra 20%	512,958	3,115	516,073
Octapharma	Cutaquig 16.5%	215,772	743	216,515
Octapharma	Gammanorm	28,732	144	28,876
Takeda	Cuvitru	352,113	814	352,927
Takeda	HyQvia	70,470	50	70,520
Total		4,405,889	775,403	5,181,292

Figure 3.1.1 Monthly number of patients on IV and SC immunoglobulin therapy 2022/23




Figure 3.1.2 Yearly number of patients on IV and SC immunoglobulin therapy 2022/23




Figure 3.2.1 Monthly recorded volume of IV and SC immunoglobulin 2022/23




Figure 3.2.2 Yearly recorded volume of IV and SC immunoglobulin 2022/23




Figure 3.3 Monthly recorded volume of the top 10 IV immunoglobulin products 2022/23




Figure 3.4 Yearly recorded volume of the top 10 IV immunoglobulin products 2017/18 - 2022/23




Figure 3.5 Monthly recorded volume of subcutaneous immunoglobulin products 2022/23




Figure 3.6 Yearly recorded volume of subcutaneous immunoglobulin products 2017/18 - 2022/23




Figure 3.7 Monthly recorded volume of immunoglobulin by supplier 2022/23




Figure 3.8 Yearly recorded volume of immunoglobulin by supplier 2017/18 - 2022/23




Table 4.1 Number of long-term patients on Ig therapy with Follow-Ups recorded 2017/18 - 2022/23

Year	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23
Long-term Patients	11,315	11,404	11,300	9,979	9,515	9,269
Follow-Ups	8,778	7,929	7,400	5,967	4,921	5,323
Percentage	78%	70%	65%	60%	51%	57%

Table 4.2 Number of short-term patients on Ig therapy with outcomes recorded 2017/18 - 2022/23

Year	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23
Short-term Patients	6,337	6,348	5,668	5,689	5,809	5,502
Outcome measures	3,303	3,396	2,323	1,912	1,472	1,209
Percentage	52%	53%	41%	34%	25%	22%

Table 4.3 ITP dosage data 2015 - 2023

Dose	2015	2016	2017	2018	2019	2020	2021	2022	2023
<= 1g/kg	44%	50%	64%	73%	81%	81%	80%	81%	85%
>= 2g/kg	56%	50%	36%	27%	19%	19%	20%	19%	15%

